Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.57 |
| ▸ | TRPV6 | Q9H1D0 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24163290 | 0.98 | SLC18A3 (0.79) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL11121512 | 0.91 | SLC18A3 (1.00) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL28702035 | 0.91 | CYP2D6 (0.93) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL7888827 | 0.91 | SLC18A3 (1.00) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL7879553 | 0.89 | SLC18A3 (0.96) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL30563652 | 0.89 | SLC18A3 (0.96) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL15184744 | 0.89 | CYP2D6 (0.83) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL13498019 | 0.87 | CYP2D6 (1.00) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL2965273 | 0.84 | SLC18A3 (0.81) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL23921799 | 0.84 | CYP2D6 (0.65) | SLC18A3CYP2D6CYP2C19SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| CN-107260726-A | Composition and method for treating nerve degenerative diseases | 考格尼申治疗股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2747768-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Cognition Therapeutics, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013029060-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | SLC18A3 9/4885CYP2D6 4309/4885CYP2C19 4656/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | SLC18A3 9/4885CYP2D6 4309/4885CYP2C19 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.